{
    "url_original": "https://www.wsj.com/articles/curevac-covid-19-vaccine-candidate-disappoints-in-key-study-11623886511?mod=business_lead_pos4",
    "url": "curevac-covid-19-vaccine-candidate-disappoints-in-key-study-11623886511",
    "title": "CureVac Shares Plunge Premarket on Disappointing Covid-19 Vaccine Trial",
    "sub_head": "Vaccine was 47% effective in an analysis of a trial, says the company, which attributed the poor performance to variants",
    "category_1": "Business",
    "category_2": "Health Care",
    "image_1_url": "https://images.wsj.net/im-355271?width=620&size=1.5",
    "image_1": "im-355271.jpg",
    "time": "2021-06-17 06:44:00"
}